The study involved a retrospective cohort of patients with ABC at the Yonsei Cancer Center who received CDK4/6i and aromatase inhibitors as first‐line therapy between January 2017 and October 2020. The gene discussed is CDK4; the disease is aneurysmal bone cyst.